Skip to main content

Table 2 Clinical markers of the study participants comparing male and female using a Chi Square test, JUSH, South West Ethiopia, 2009

From: Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia

Characteristics Male
No. (%)
Female
No. (%)
Total
No. (%)
P - value
WHO disease stage when HAART started (N = 319)     0.075
I 7(4.9) 5(2.9) 12(3.8)  
II 35(24.3) 43(24.6) 78(24.5)  
III 85(59.0) 88(50.3) 173(54.2)  
IV 17(11.8) 39(22.3) 56(17.6)  
CD4 count when the treatment was started (N = 305)     0.298
≥ 500 1(0.7) 0(0.0) 1(0.3)  
201-499 43(30.5) 44(26.8) 87(28.5)  
≤ 200 97(68.8) 120(73.2) 217(71.1)  
Recent CD4 count (N = 257)     0.111
≥ 500 22(18.5) 38(27.5) 60(23.3)  
201-499 73(61.3) 82(59.4) 155(60.3)  
≤ 200 24(20.2) 18(13.1) 42(16.3)  
Duration of treatment in months (N = 319)     0.877
3.0-12.0 25(17.4) 28(16.0) 53(16.6)  
12.1-24.0 35(24.3) 40(22.9) 75(23.5)  
≥ 24.1 84(58.3) 107(61.1) 191(59.9)  
Treatment regimen(N = 319)     0.549
d4t (30)- 3TC-NVP 88(61.1) 115(65.7) 203(63.6)  
d4t (40)- 3TC-NVP 12(8.3) 14(8.0) 26(8.2)  
d4t (30)- 3TC-EFV 21(14.6) 17(9.7) 38(11.9)  
d4t (40)- 3TC-EFV 5(3.5) 3(1.7) 8(2.5)  
AZT-3TC-NVP 16(11.1) 25(14.3) 41(12.9)  
AZT-3TC-EFV 2(1.4) 1(0.6) 3(0.9)